Dear MTCONS Members, You are cordially invited to the April 3, 2025 Chapter Meeting at Maggiano's Little Italy.
The Topic for the evening is: Exploring the Role of NUBEQA (darolutamide) in mHSPC in Combination With Docetaxel and in nmCRPC PPNUB-US-3389-1
NUBEQA® (darolutamide) is an androgen receptor inhibitor indicated for the treatment of adult patients with1:
• Non-metastatic castration-resistant prostate cancer (nmCRPC)
• Metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel
SPEAKER:
Kimberly Nichols, Oncology Nurse Educator, Bayer Healthcare
DATE/TIME:
Thursday, April 3, 2025
Registration: 5:30 PM
Chapter Meeting and Presentation: 6:00 PM
Venue:
Maggiano's Little Italy
3106 West End Ave
Nashville, TN 37203
